Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 435

1.

Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.

Weigand M, Hantel P, Kreienberg R, Waltenberger J.

Angiogenesis. 2005;8(3):197-204. Epub 2005 Nov 19.

PMID:
16328160
2.

Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.

Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, Oue N, Yasui W, Chayama K.

Clin Cancer Res. 2008 Nov 15;14(22):7205-14. doi: 10.1158/1078-0432.CCR-08-0818.

3.

Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.

Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ.

Int J Oncol. 2008 Mar;32(3):585-92.

PMID:
18292935
4.

Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.

Balthasar S, Bergelin N, Löf C, Vainio M, Andersson S, Törnquist K.

Endocr Relat Cancer. 2008 Jun;15(2):521-34. doi: 10.1677/ERC-07-0253.

5.

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.

Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62.

6.

Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells.

Sakamoto H, Sakamaki T, Kanda T, Tsuchiya Y, Sato M, Sato H, Oyama Y, Sawada Y, Tamura J, Nagai R, Kurabayashi M.

Circ J. 2004 May;68(5):488-93.

7.
8.

An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.

Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A, Culig Z.

Eur J Cancer. 2004 May;40(7):1066-72.

PMID:
15093584
9.

Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt.

Byeon SH, Lee SC, Choi SH, Lee HK, Lee JH, Chu YK, Kwon OW.

Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1190-7. doi: 10.1167/iovs.09-4144. Epub 2009 Oct 15.

PMID:
19834034
10.

Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.

Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D.

Oncogene. 2005 Dec 1;24(54):8025-37.

PMID:
16116481
11.
12.

A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells.

Akahane M, Akahane T, Shah A, Okajima E, Thorgeirsson UP.

Anticancer Res. 2005 Mar-Apr;25(2A):701-7.

13.

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.

Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.

Clin Cancer Res. 2006 Nov 1;12(21):6573-84.

14.

RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.

Eur J Cancer. 2011 Oct;47(15):2353-63. doi: 10.1016/j.ejca.2011.05.006. Epub 2011 Jun 15.

PMID:
21680174
15.

Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.

Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.

Oncogene. 2005 Jan 27;24(5):790-800. Erratum in: Oncogene. 2005 Jun 9;24(25):4164.

PMID:
15592523
16.

Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism.

Gaudio E, Barbaro B, Alvaro D, Glaser S, Francis H, Ueno Y, Meininger CJ, Franchitto A, Onori P, Marzioni M, Taffetani S, Fava G, Stoica G, Venter J, Reichenbach R, De Morrow S, Summers R, Alpini G.

Gastroenterology. 2006 Apr;130(4):1270-82.

PMID:
16618418
17.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
18.

[Autocrine stimulation of receptor-tyrosine kinases (RTK) in human tumor cell lines in vitro: therapeutic implications].

Gaumann A, Groot M, Drexler HC, Breier G.

Verh Dtsch Ges Pathol. 2003;87:232-9. German.

PMID:
16888917
19.

Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.

Schmidt M, Voelker HU, Kapp M, Dietl J, Kammerer U.

Anticancer Res. 2008 May-Jun;28(3A):1719-24.

20.

Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.

Tian X, Song S, Wu J, Meng L, Dong Z, Shou C.

Biochem Biophys Res Commun. 2001 Aug 24;286(3):505-12.

PMID:
11511087

Supplemental Content

Support Center